The Technical Analyst
Apyx Medical Corp [APYX]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Medical Devices
Apyx Medical Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.37% $3.70
Last updated: 16 May 2022 @ 12:01 pm
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 127.48 mill |
| EPS: | -0.442 |
| P/E: | 0.000 |
| Earnings Date: | Aug 10, 2022 |
| SharesOutstanding: | 34.45 mill |
| Avg Daily Volume: | 0.148 mill |
| RATING 2022-05-13 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.60 (24.39%) $0.902 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.433 ( +/- 11.86%) Range: 3.22 - 4.08 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-03-21 | Swandal Craig A. | Sell | 17 000 | Stock Option (Option to Buy) |
| 2022-03-21 | Swandal Craig A. | Buy | 17 000 | Common Stock |
| 2022-01-19 | Hornsby Todd | Buy | 100 000 | Stock Option (Option to Buy) |
| 2022-01-19 | Citronowicz Moshe | Buy | 72 000 | Stock Option (Option to Buy) |
| 2022-01-19 | Goodwin Charles D. Ii | Buy | 243 000 | Stock Option (Option to Buy) |
| INSIDER POWER |
|---|
| 85.83 |
| Last 100 transactions |
| Buy: 12 471 461 | Sell: 103 241 |
Forecast:
13:30 - $3.69
Live Trading Signals (every 1 min)
Forecast
1: 12:00 - $3.71
Forecast 2: 12:50 - $3.66
Forecast 3: 13:30 - $3.69
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.70 (1.37% ) |
| Volume | 0.0426 mill |
| Avg. Vol. | 0.148 mill |
| % of Avg. Vol | 28.79 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APYX
243 Signals | Accuracy: 25.51% | Accuracy Buy: 26.45% | Accuracy Sell: 24.59%
Avg return buy: -0.17 % | Avg return sell: -0.08 %
$1 invested is now $0.80 or -20.02% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 11:54 | buy | $3.70 | N/A | Active |
|---|---|---|---|---|
| May 16 - 10:32 | sell | $3.74 | $3.70 @ May 16 - 11:53 | -1.07% |
| May 16 - 10:03 | buy | $3.70 | $3.75 @ May 16 - 10:27 | 1.22% |
| May 13 - 16:01 | sell | $3.65 | $3.69 @ May 16 - 10:02 | 1.10% |
| May 13 - 15:57 | buy | $3.68 | $3.66 @ May 13 - 15:59 | -0.54% |
| May 13 - 15:51 | sell | $3.64 | $3.68 @ May 13 - 15:56 | 1.10% |
| May 13 - 15:21 | buy | $3.65 | $3.64 @ May 13 - 15:50 | -0.27% |
| May 13 - 15:05 | sell | $3.65 | $3.65 @ May 13 - 15:20 | 0.14% |
| May 13 - 14:44 | buy | $3.61 | $3.65 @ May 13 - 15:04 | 0.97% |
| May 13 - 13:53 | sell | $3.61 | $3.61 @ May 13 - 14:43 | 0.14% |
APYX
Latest Press Releases
2022-04-25 14:00:00 - Press Release
Glancy Prongay & Murray Llp, A Leading Securities Fraud Law Firm, Continues Its Investigation Of Apyx Medical Corporation (apyx) On Behalf Of Investors
Los angeles--(business wire)--glancy prongay & murray llp (“gpm”), a leading national shareholder rights law firm, continues its investigation on behalf of apyx medical corporation (“apyx” or the “company”) (nasdaq: apyx) investors concerning the company's possible violations of the federal securities laws. if you suffered a loss on your apyx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your con
2022-04-23 13:00:00 - Press Release
The Law Offices Of Frank R. Cruz Continues Investigation Of Apyx Medical Corporation (apyx) On Behalf Of Investors
Los angeles--(business wire)--the law offices of frank r. cruz continues its investigation of apyx medical corporation (“apyx” or the “company”) (nasdaq: apyx) on behalf of investors concerning the company's possible violations of federal securities laws. if you are a shareholder who suffered a loss, click here to participate. on march 14, 2022, apyx disclosed that the u.s. food and drug administration (“fda”) would be posting a medical device safety communication (“mdsc”) related to the compan
2022-04-22 17:24:00 - Press Release
Investor Alert: Law Offices Of Howard G. Smith Continues Its Investigation Of Apyx Medical Corporation (apyx) On Behalf Of Investors
Bensalem, pa.--(business wire)--law offices of howard g. smith continues its investigation on behalf of apyx medical corporation (“apyx” or the “company”) (nasdaq: apyx) investors concerning the company's possible violations of federal securities laws. on march 14, 2022, apyx disclosed that the u.s. food and drug administration (“fda”) would be posting a medical device safety communication (“mdsc”) related to the company's advanced energy products. the company further disclosed that “[b]ased on
2022-04-21 21:00:00 - Press Release
Apyx Alert: Bragar Eagel & Squire, P.c. Is Investigating Apyx Medical Corp. On Behalf Of Apyx Stockholders And Encourages Investors To Contact The Firm
New york--(business wire)-- #action--bragar eagel & squire, p.c., a nationally recognized stockholder rights law firm, is investigating potential claims against apyx medical corp. (“apyx” or the “company”) (nasdaq: apyx) on behalf of apyx stockholders. our investigation concerns whether apyx has violated the federal securities laws and/or engaged in other unlawful business practices. click here to participate in the action. on march 14, 2022, apyx disclosed that the u.s. food and drug administration
2022-04-21 11:00:00 - Press Release
Investor Alert: Law Offices Of Howard G. Smith Announces Investigation Of Apyx Medical Corporation (apyx) On Behalf Of Investors
Bensalem, pa.--(business wire)--law offices of howard g. smith announces an investigation on behalf of apyx medical corporation (“apyx” or the “company”) (nasdaq: apyx) investors concerning the company's possible violations of federal securities laws. on march 14, 2022, apyx disclosed that the u.s. food and drug administration (“fda”) would be posting a medical device safety communication (“mdsc”) related to the company's advanced energy products. the company further disclosed that “[b]ased on
Latest News
2022-05-12 14:21:07 - Seeking Alpha
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q1 2022 Results - Earnings Call Transcript
Apyx Medical Corporation (NASDAQ:APYX ) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Charles Goodwin - President & Chief Executive Officer Tara Semb - Chief Financial Officer, Treasurer & Secretary Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Operator Hello, and welcome, ladies and gentlemen to the First Quarter of 2022 Earnings Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen-only mode.
2022-05-12 09:47:33 - Zacks Investment Research
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
Apyx (APYX) delivered earnings and revenue surprises of -30.77% and 7.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-04-04 16:05:00 - Business Wire
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2022 Financial Results on May 12, 2022
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the first quarter of fiscal year 2022 will be released before the market opens on Thursday, May 12th. Management will host a conference call at 8:00 a.m. Eastern Time on
2022-03-17 11:32:08 - Seeking Alpha
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q4 2021 Results - Earnings Call Transcript
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q4 2021 Results - Earnings Call Transcript
2022-01-27 07:30:00 - Business Wire
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 17, 2022
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2021 will be released before the market opens on Thursday, March 17th. Management will host a conference call at 8:00 a.m. Eastern Tim
2021-11-11 21:45:38 - Seeking Alpha
Apyx Medical Corp (APYX) CEO Charles Goodwin on Q3 2021 Results - Earnings Call Transcript
Apyx Medical Corp (APYX) CEO Charles Goodwin on Q3 2021 Results - Earnings Call Transcript
2021-11-04 16:47:46 - Zacks Investment Research
Earnings Preview: Apyx Medical (APYX) Q3 Earnings Expected to Decline
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-10-04 16:05:00 - Business Wire
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2021 Financial Results on November 11, 2021
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the third quarter of fiscal year 2021 will be released after the market closes on Thursday, November 11th. Management will host a conference call at 5:00 p.m. Eastern Ti
2021-09-28 10:05:28 - Zacks Investment Research
Apyx (APYX) Moves 10.9% Higher: Will This Strength Last?
Apyx (APYX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2021-08-30 07:30:00 - Business Wire
Apyx Medical Corporation Announces Appointment of Wendy Levine to the Company's Board of Directors
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Wendy Levine to the Board of Directors, effective August 25, 2021. Ms. Levine will serve as a Director and member of the Regulatory Compliance Committee. “I am pleas